Executive team
Dr Ansar Jawiad, CEO
Ansar has over 20 years scientific, development, regulatory and commercialisation experience across large pharma to start-ups. Developing medicines and diagnostics from discovery to commercialisation.
He has held senior leadership roles at AstraZeneca, Merck and BMS leading global teams across R&D, Regulatory and Commercial, contributing to development, approval, and commercialisation of more than ten products.
As a biotech entrepreneur he has helped many start-ups build out their teams, license assets, develop strategy and raise investment.
Ansar holds a BSc in Molecular Genetics, PhD in Statistical Genetics and an Associateship of King’s College London in Philosophy and Theology
Abdul Butt, SVP, Quality and Regulatory
Abdul has over 25 years expertise in Global Quality, Regulatory Affairs and EU QP. He has overseen quality and regulatory affairs for a variety of companies globally, including GSK, Pfizer, AstraZeneca, Fisher Clinical, Almac, Catalent Pharma Solutions and PCI Pharma Solutions.
Abdul holds a BSc in Chemistry from the University of Manchester Institute of Technology (UMIST), UK.
Collin Newbould, CSO
Collin has over 25 years experience in the pharmaceutical sector. He has held extensive leadership roles in Regulatory and Quality in global pharmaceutical organisations, including Wasdell Group, PCI Pharma Services, Penn Pharmaceutical Services and Catalent Pharma Solutions.
Colin holds a BSc 1st Class in Chemistry with Analytical Chemistry and Toxicology from the University of Hull, UK.